FDA has identified it as an unapproved new drug (Manookian/Melanocorp Electronic Reading Room notice); never completed clinical development or received approval for any indication.
Melanotan 2 is a synthetic, cyclic, non-selective analogue of alpha-MSH that activates multiple melanocortin receptors: MC1R (driving melanogenesis, its intended research use) and MC3R/MC4R (implicate...
Melanotan 2 is a synthetic, cyclic, non-selective analogue of alpha-MSH that activates multiple melanocortin receptors: MC1R (driving melanogenesis, its intended research use) and MC3R/MC4R (implicated in off-target appetite and sexual-function effects observed in early pharmacology studies). Its lack of receptor selectivity relative to afamelanotide is understood to be why it was never advanced as an approved drug.
Sexual Medicine · 2021
Documents acute ischemic priapism after self-administered subcutaneous Melanotan 2 injection, requiring surgical decompression after failed aspiration.
View Source →Annals of Internal Medicine · 2013
Case report linking Melanotan injection to posterior reversible encephalopathy syndrome (PRES), a serious acute neurological syndrome.
View Source →Clinical Toxicology · 2013
Reports a Melanotan 2 overdose presenting with priapism and rhabdomyolysis.
View Source →Life Sciences · 1996
Original Phase I dose-escalation study in 3 male volunteers documented tanning activity along with nausea, somnolence, fatigue, a stretching/yawning complex, and prolonged spontaneous erections.
View Source →